- Net Sales Volume change was higher than estimated at +1%, over an estimated -0.71%.
- For Personal care, net sales volume increase was 2%, above the expected -0.13%.
- K-C Professional Net Sales Volume Change was -2%, better than the expected decline of -2.63%.
- The Adjusted EPS was registered at $2.01, beating the estimate of $1.64.
- Net sales achieved were $5.15 billion, surpassing the estimated $5.08 billion.
- Personal Care net sales stood at $2.71 billion, over the expected $2.69 billion.
- Consumer Tissue net sales was reported to be $1.60 billion, above the forecasted $1.57 billion.
- K-C Professional Net Sales came in at $823 million, higher than the estimated $808.9 million.
- Corporate & Other Net Sales recorded at $14 million, over the estimated figure of $10.3 million.
- The organic sales were noted at +6%, better than the anticipated +2.48%.
- For Personal Care, organic sales increase was +10%, higher than the +4.33% predicted.
- Consumer Tissue organic sales were stable at 0%, beating the estimated drop of -1.23%.
- K-C Professional Organic Sales Change came in positive at +2%, over the estimated decline of -2.47%.
- The company expects to grow its organic net sales in mid-single digits in 2024, higher than their previous expectation.
- The company mentioned that reported net sales for the year might be affected by 400 basis points of currency translation and 120 basis points from divestitures.
- Adjusted EPS for the year is expected to grow at a low-teens percentage rate on a constant-currency basis, an increase from the previous forecast.
- The company anticipates its adjusted operating profit growth to be at a low-teens percentage rate on a constant-currency basis for the year.
Kimberly Clark on Smartkarma
Independent analysts on Smartkarma have been closely covering Kimberly-Clark Corporation, providing valuable insights into its recent performance and strategic moves. Baptista Research, in their report “Kimberly-Clark Corporation: Optimized pricing and volume mix strategy could be a game changer? – Major Drivers,” highlighted the company’s steady growth and challenges in the fourth quarter and full year 2023 results. Kimberly-Clark is focusing on expanding markets and elevating categories for growth, with promising early results despite supply constraints affecting market share.
Furthermore, in another report by Baptista Research titled “Kimberly-Clark Corporation: Is It The Market’s Hidden Gem? – Major Drivers,” analysts noted mixed results for the previous quarter, with revenues slightly below analyst expectations. The strategic decision to exit the Brazil tissue business impacted net sales, specifically in Consumer Tissue and Professional segments. Despite this, Consumer Tissue still managed 2% organic growth, driven by a strong 4% growth in North America due to robust demand for dry baths and towels.
A look at Kimberly Clark Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Kimberly-Clark Corporation, a global health and hygiene company renowned for consumer product manufacturing, shows a promising long-term outlook. The Smartkarma Smart Scores highlight its solid performance in dividend and momentum, with above-average scores in growth. While the value and resilience scores are not as high, Kimberly Clark‘s core strengths in dividend and momentum indicate a positive trajectory for the company.
Specializing in products like diapers, tissues, and disposable face masks, Kimberly-Clark’s global presence positions it well for sustained growth. With a strong emphasis on dividends and a favorable momentum trend, the company’s future looks bright in the consumer goods sector despite being rated lower in value and resilience according to the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
